MIMEDX Engages Nordic Bioscience Clinical Development A/S to Propel Registrational Trials of Placental Biologic Injectable for Knee Osteoarthritis
June 15, 2022 08:30 ET
|
MiMedx Group, Inc
Image Analysis Group to Provide Imaging Strategy and Advanced Imaging Analytics in Support of MIMEDX’s Knee Osteoarthritis Clinical Trial Program MARIETTA, Ga., June 15, 2022 (GLOBE NEWSWIRE) --...
MIMEDX Shareholders Vote to Approve All Proposals at the 2022 Annual Meeting
June 07, 2022 16:05 ET
|
MiMedx Group, Inc
Dr. Phyllis Gardner and James L. Bierman Reelected to Board of Directors Company Also Receives Approvals for Say-on-Pay Proposal and Qualified Employee Stock Purchase Plan MARIETTA, Ga., June 07,...
MIMEDX Reminds Shareholders to Pre-Register for the Upcoming Virtual 2022 Annual Meeting of Shareholders
June 03, 2022 08:00 ET
|
MiMedx Group, Inc
Deadline to Pre-Register is 9:00 a.m. Eastern Time on June 6, 2022 Pre-Registration Required to Attend Annual Meeting Visit www.votemimedx.com for Instructions on How to Pre-Register MARIETTA,...
MIMEDX Addresses Presentation by Prescience Point
June 02, 2022 08:03 ET
|
MiMedx Group, Inc
Company Highlights Factually Accurate Information Already Provided Urges Shareholders to Vote “FOR” MIMEDX’s Highly Qualified and Independent Directors – James L. Bierman and Phyllis Gardner, M.D. On...
MIMEDX Board Chair Dr. M. Kathleen Behrens Writes Letter to Fellow Shareholders
May 31, 2022 16:05 ET
|
MiMedx Group, Inc
Urges Shareholders to Vote “FOR” MIMEDX’s Highly Qualified and Independent Directors – James L. Bierman and Phyllis Gardner, M.D. on the WHITE Proxy Card Today MARIETTA, Ga., May 31, 2022 ...
MIMEDX Receives $4.6 Million Award from the Department of Defense to Advance the Treatment of Combat Casualty Wounds and Burns
May 31, 2022 08:00 ET
|
MiMedx Group, Inc
Funding Enables Evaluation of PURION® Processed Placental Tissue as an Innovative Approach in the Management of Acute Military-Related Injuries, Addressing a Critical Unmet Need MARIETTA, Ga., May ...
Leading Independent Proxy Advisory Firm ISS Recommends that MIMEDX Shareholders Vote “FOR ALL” of the Company’s Proposals
May 25, 2022 17:26 ET
|
MiMedx Group, Inc
Follows Previous Recommendation from Glass Lewis in Support of ALL Proposals Recommends Shareholders Vote “FOR” Both of MIMEDX’s Highly Qualified Director Nominees – James L. Bierman and Phyllis...
Leading Independent Proxy Advisory Firm Glass Lewis Recommends that MIMEDX Shareholders Vote “FOR ALL” of the Company’s Proposals
May 20, 2022 09:00 ET
|
MiMedx Group, Inc
Recommends Shareholders Vote “FOR” Both of MIMEDX’s Highly Qualified Director Nominees – James L. Bierman and Phyllis Gardner, M.D. Recommends Shareholders Vote “FOR” the Company’s Say-on-Pay...
MIMEDX Investor Presentation Highlights Clear Strategy for Value Creation
May 18, 2022 16:18 ET
|
MiMedx Group, Inc
Decisive, Positive Actions Taken to Stabilize and Transform MIMEDX Have Established Strong, New Foundation for Growth Company Urges Shareholders to Vote “FOR” Both Highly Qualified Director Nominees...
MIMEDX Mails Letter to Shareholders
May 16, 2022 08:00 ET
|
MiMedx Group, Inc
Highlights Successful Execution of Transformation Strategy Under CEO Tim Wright Reaffirms Commitment to Enhancing Value for ALL Shareholders Urges Shareholders to Vote “FOR” Both of MIMEDX’s...